# C19orf33

## Overview
C19orf33, or chromosome 19 open reading frame 33, is a gene that encodes a protein involved in crucial cellular processes, including immune response regulation and cellular signaling. The protein, also referred to as C19orf33, is not categorized as a kinase, receptor, or transmembrane protein but plays a significant role in both the cytoplasm and nucleus of cells. It is implicated in cell cycle regulation and apoptosis, contributing to cellular homeostasis and the organism's defense mechanisms against pathogens. The gene's expression and function have been linked to various clinical conditions, including cancer and immune disorders, highlighting its potential as a biomarker for disease prognosis and treatment response (Fehrmann2011TranseQTLs; Li2021Predicting; Song2024Identification).

## Function
C19orf33, also known as chromosome 19 open reading frame 33, encodes a protein that plays a significant role in various cellular processes, particularly in the regulation of immune responses and cellular signaling pathways. This protein is active in both the cytoplasm and nucleus of cells, where it contributes to critical functions such as cell cycle regulation and apoptosis. By participating in these processes, C19orf33 helps maintain cellular homeostasis, ensuring that cells function properly and respond appropriately to internal and external stimuli.

In the cytoplasm, the protein encoded by C19orf33 is involved in signaling pathways that regulate immune responses, which are essential for protecting the organism against pathogens and maintaining immune system balance. In the nucleus, its role in cell cycle regulation is crucial for proper cell division and growth, preventing uncontrolled cell proliferation that could lead to tumorigenesis. Additionally, its involvement in apoptosis, the programmed cell death process, is vital for eliminating damaged or unnecessary cells, thereby contributing to tissue homeostasis and preventing the accumulation of potentially harmful cells.

Understanding the function of C19orf33 provides insights into its potential implications in disease states, as disruptions in its activity could lead to immune system disorders or contribute to the development of cancer.

## Clinical Significance
C19orf33 has been implicated in various diseases and conditions through alterations in its expression levels and interactions. In cancer research, C19orf33 is identified as a significant predictive gene for drug sensitivity, particularly in relation to kinase inhibitors. Its expression is positively correlated with resistance to DNA synthesis inhibitors, microtubule assembly inhibitors, and cell cycle inhibitors, while showing increased sensitivity to kinase inhibitors (Li2021Predicting). In triple-negative breast cancer (TNBC), C19orf33 is part of a 12-gene signature associated with prognosis and immune-related biomarkers. It is frequently expressed in tumor cells and is linked to the clinical effectiveness of TNBC immunotherapy (Song2024Identification). 

C19orf33 is also involved in blood coagulation processes, as suggested by its co-expression with GP9 in peripheral blood and its association with mean platelet volume (Fehrmann2011TranseQTLs). In the context of acute myeloid leukemia (AML), C19orf33 is part of differentially regulated gene networks in azacitidine-resistant cell lines, although its direct role in resistance is not clearly established (Park2024Differential). These findings highlight the potential of C19orf33 as a biomarker and its involvement in various disease mechanisms.


## References


[1. (Fehrmann2011TranseQTLs) Rudolf S. N. Fehrmann, Ritsert C. Jansen, Jan H. Veldink, Harm-Jan Westra, Danny Arends, Marc Jan Bonder, Jingyuan Fu, Patrick Deelen, Harry J. M. Groen, Asia Smolonska, Rinse K. Weersma, Robert M. W. Hofstra, Wim A. Buurman, Sander Rensen, Marcel G. M. Wolfs, Mathieu Platteel, Alexandra Zhernakova, Clara C. Elbers, Eleanora M. Festen, Gosia Trynka, Marten H. Hofker, Christiaan G. J. Saris, Roel A. Ophoff, Leonard H. van den Berg, David A. van Heel, Cisca Wijmenga, Gerard J. te Meerman, and Lude Franke. Trans-eqtls reveal that independent genetic variants associated with a complex phenotype converge on intermediate genes, with a major role for the hla. PLoS Genetics, 7(8):e1002197, August 2011. URL: http://dx.doi.org/10.1371/journal.pgen.1002197, doi:10.1371/journal.pgen.1002197. This article has 292 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1002197)

[2. (Li2021Predicting) Yuanyuan Li, David M. Umbach, Juno M. Krahn, Igor Shats, Xiaoling Li, and Leping Li. Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines. BMC Genomics, April 2021. URL: http://dx.doi.org/10.1186/s12864-021-07581-7, doi:10.1186/s12864-021-07581-7. This article has 33 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12864-021-07581-7)

[3. (Song2024Identification) Xiao-Qing Song and Zhi-Ming Shao. Identification of immune-related prognostic biomarkers in triple-negative breast cancer. Translational Cancer Research, 13(4):1707â€“1720, April 2024. URL: http://dx.doi.org/10.21037/tcr-23-1554, doi:10.21037/tcr-23-1554. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.21037/tcr-23-1554)

[4. (Park2024Differential) Heewon Park and Satoru Miyano. Differential gene regulatory network analysis between azacitidine-sensitive and -resistant cell lines. International Journal of Molecular Sciences, 25(6):3302, March 2024. URL: http://dx.doi.org/10.3390/ijms25063302, doi:10.3390/ijms25063302. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms25063302)